Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maitake Mushroom Extract in Myelodysplastic Syndrome
NCT01099917Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2010
- Primary completion
- Sep 2014
- Modality
- Botanical drug
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bli-1401 in myelodysplastic syndrome (MDS), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Changes in Neutrophil Counts at 12 weeks. Started Apr 2010; status: completed.
02
Drugs
bli-1401
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01099917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01099917.